A Phase I First-in-human, Open Label, Multicenter, Dose Escalation and Cohort Expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of BB-1705 in Patients With Locally Advanced/Metastatic Solid Tumors
Latest Information Update: 22 Dec 2023
At a glance
- Drugs BB 1701 (Primary)
- Indications Advanced breast cancer; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Bliss Biopharmaceutical
Most Recent Events
- 14 Dec 2023 Planned End Date changed from 1 Jun 2025 to 1 Dec 2025.
- 14 Dec 2023 Planned primary completion date changed from 1 Dec 2024 to 1 Dec 2025.
- 06 Feb 2023 Status changed from not yet recruiting to recruiting.